In this series of global leaders, we will highlight an international non-profit healthcare organization that provides a bridge between patient care and the complexities of medicine. This area of healthcare is often referred to as Bioethics and in 2011, Dr. Ana Lita and Dr. Charles Debrovner co-founded Global Bioethics Initiative (GBI). This organization offers an all-inclusive resource that allow young and established healthcare professionals a place to learn about essential information about the ethical dilemmas in medicine. GBI is unique in their approach in that they make Bioethics approachable and tangible to everyone. This first installment of this series will layout the reasons behind making bioethics global, the reasons for forming GBI, and their educational programs.
WHY GLOBAL BIOETHICS?
People are beginning to appreciate more deeply the bonds between human well-being and the unrelenting pace of medical and technological advances. The progress made in life sciences, medicine and biotechnology in recent years has provided us with exciting and novel ways of treating, preventing, and curing human diseases. Some (relatively) recent notable and controversial developments in medical science and biotechnology include: markets in organs and transplantation therapy, the accessibility of biotechnological developments in reproductive healthcare, genetic testing and gene therapy, the End-of-Life, the “right to die” and palliative care, as well as life extension, healthy aging and regenerative medicine. While the positive impact of these advances on individuals and societies must be applauded, the ethical consequences of such developments necessitate our attention. The increasing power that new biotechnologies offer us requires that we consider not only whether something can be done, but whether it should it be done.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.